281 related articles for article (PubMed ID: 25284480)
41. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
42. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
43. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages.
Luyendyk JP; Schabbauer GA; Tencati M; Holscher T; Pawlinski R; Mackman N
J Immunol; 2008 Mar; 180(6):4218-26. PubMed ID: 18322234
[TBL] [Abstract][Full Text] [Related]
44. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
[TBL] [Abstract][Full Text] [Related]
45. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Furuya F; Hanover JA; Cheng SY
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1780-5. PubMed ID: 16446424
[TBL] [Abstract][Full Text] [Related]
46. Increased serum leptin protects from adiposity despite the increased glucose uptake in white adipose tissue in mice lacking p85alpha phosphoinositide 3-kinase.
Terauchi Y; Matsui J; Kamon J; Yamauchi T; Kubota N; Komeda K; Aizawa S; Akanuma Y; Tomita M; Kadowaki T
Diabetes; 2004 Sep; 53(9):2261-70. PubMed ID: 15331535
[TBL] [Abstract][Full Text] [Related]
47. Somatic mutations of PIK3R1 promote gliomagenesis.
Quayle SN; Lee JY; Cheung LW; Ding L; Wiedemeyer R; Dewan RW; Huang-Hobbs E; Zhuang L; Wilson RK; Ligon KL; Mills GB; Cantley LC; Chin L
PLoS One; 2012; 7(11):e49466. PubMed ID: 23166678
[TBL] [Abstract][Full Text] [Related]
48. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Weber GL; Parat MO; Binder ZA; Gallia GL; Riggins GJ
Oncotarget; 2011 Nov; 2(11):833-49. PubMed ID: 22064833
[TBL] [Abstract][Full Text] [Related]
49. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling.
Walsh CM; Fruman DA
J Clin Invest; 2014 Sep; 124(9):3688-90. PubMed ID: 25133419
[TBL] [Abstract][Full Text] [Related]
50. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
51. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
52. Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-kappaB-dependent gene transcription in BCG-stimulated macrophages through promotion of p65/p300 binding.
Darieva Z; Lasunskaia EB; Campos MN; Kipnis TL; Da Silva WD
J Leukoc Biol; 2004 Apr; 75(4):689-97. PubMed ID: 14742634
[TBL] [Abstract][Full Text] [Related]
53. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK
Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981
[TBL] [Abstract][Full Text] [Related]
54. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors.
Shen YH; Godlewski J; Zhu J; Sathyanarayana P; Leaner V; Birrer MJ; Rana A; Tzivion G
J Biol Chem; 2003 Jul; 278(29):26715-21. PubMed ID: 12738796
[TBL] [Abstract][Full Text] [Related]
55. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
56. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways.
Campbell M; Allen WE; Sawyer C; Vanhaesebroeck B; Trimble ER
Circ Res; 2004 Aug; 95(4):380-8. PubMed ID: 15242975
[TBL] [Abstract][Full Text] [Related]
57. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
58. p85alpha regulates osteoblast differentiation by cross-talking with the MAPK pathway.
Wu X; Chen S; Orlando SA; Yuan J; Kim ET; Munugalavadla V; Mali RS; Kapur R; Yang FC
J Biol Chem; 2011 Apr; 286(15):13512-21. PubMed ID: 21324896
[TBL] [Abstract][Full Text] [Related]
59. New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes.
Herrero-Gonzalez S; Di Cristofano A
Cancer Discov; 2011 Jul; 1(2):106-7. PubMed ID: 22586352
[TBL] [Abstract][Full Text] [Related]
60. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
